Chinook Therapeutics Future Growth
Future criteria checks 2/6
Chinook Therapeutics is forecast to grow earnings and revenue by 22.6% and 63.8% per annum respectively while EPS is expected to grow by 28% per annum.
Key information
22.6%
Earnings growth rate
28.0%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 63.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 10 Aug 2023 |
Recent future growth updates
Recent updates
Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?
May 28
Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth
Feb 14Chinook Therapeutics: Multiple Shots On Goal For IgAN
Aug 31Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%
Aug 12Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line
Aug 08Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease
Jul 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 80 | -247 | -286 | -253 | 8 |
| 12/31/2024 | 13 | -284 | -289 | -262 | 11 |
| 12/31/2023 | 3 | -253 | -290 | -243 | 5 |
| 6/30/2023 | 6 | -246 | -177 | -174 | N/A |
| 3/31/2023 | 5 | -216 | -146 | -143 | N/A |
| 12/31/2022 | 6 | -188 | -119 | -117 | N/A |
| 9/30/2022 | 57 | -118 | -105 | -103 | N/A |
| 6/30/2022 | 54 | -92 | -104 | -103 | N/A |
| 3/31/2022 | 54 | -97 | -101 | -99 | N/A |
| 12/31/2021 | 52 | -103 | -105 | -103 | N/A |
| 9/30/2021 | 1 | -160 | -124 | -122 | N/A |
| 6/30/2021 | 1 | -149 | -105 | -104 | N/A |
| 3/31/2021 | 1 | -114 | -82 | -80 | N/A |
| 12/31/2020 | 1 | -82 | -57 | -56 | N/A |
| 9/30/2020 | N/A | -52 | -19 | -19 | N/A |
| 6/30/2020 | N/A | -54 | -17 | -16 | N/A |
| 3/31/2020 | N/A | -48 | -16 | -15 | N/A |
| 12/31/2019 | N/A | -47 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KDNY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KDNY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KDNY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KDNY's revenue (63.8% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: KDNY's revenue (63.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KDNY's Return on Equity is forecast to be high in 3 years time